Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 23;23(12):3069.
doi: 10.3390/molecules23123069.

Novel 5'-Norcarbocyclic Pyrimidine Derivatives as Antibacterial Agents

Affiliations

Novel 5'-Norcarbocyclic Pyrimidine Derivatives as Antibacterial Agents

Anastasia L Khandazhinskaya et al. Molecules. .

Abstract

A series of novel 5'-norcarbocyclic derivatives of 5-alkoxymethyl or 5-alkyltriazolyl-methyl uracil were synthesized and the activity of the compounds evaluated against both Gram-positive and Gram-negative bacteria. The growth of Mycobacterium smegmatis was completely inhibited by the most active compounds at a MIC99 of 67 μg/mL (mc²155) and a MIC99 of 6.7⁻67 μg/mL (VKPM Ac 1339). Several compounds also showed the ability to inhibit the growth of attenuated strains of Mycobacterium tuberculosis ATCC 25177 (MIC99 28⁻61 μg/mL) and Mycobacterium bovis ATCC 35737 (MIC99 50⁻60 μg/mL), as well as two virulent strains of M. tuberculosis; a laboratory strain H37Rv (MIC99 20⁻50 μg/mL) and a clinical strain with multiple drug resistance MS-115 (MIC99 20⁻50 μg/mL). Transmission electron microscopy (TEM) evaluation of M. tuberculosis H37Rv bacterial cells treated with one of the compounds demonstrated destruction of the bacterial cell wall, suggesting that the mechanism of action for these compounds may be related to their interactions with bacteria cell walls.

Keywords: 5′-norcarbocyclic nucleosides; Mycobacterium tuberculosis; antibacterial activity; uracil derivatives.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Previously reported anti-M. tuberculosis nucleosides.
Figure 2
Figure 2
Examples of anti-Mtb 5′-norcarbocyclic nucleosides.
Figure 3
Figure 3
Target compounds.
Scheme 1
Scheme 1
(i) Pd/C, H2, MeOH; (ii) Ac2O, Py; (iii) Br2, DCE, hv, 83 °C.
Scheme 2
Scheme 2
(i) ROH; (ii) K2CO3, MeOH; (iii) NaN3, DMF, 40 °C; (iv) RC≡CH, CuSO4·5H2O, sodium ascorbate, CH2Cl2/H2O (1:1).
Figure 4
Figure 4
Transmission electron microscopy of M. tuberculosis H37Rv bacterial cells. Control bacterial cells were grown for 4 days in enriched Dubois medium (A) or in enriched Dubois medium containing DMSO/Twin-80/H2O solution without compound 3 (B). Bacterial cells after treatment with compound 3 (50 µg/mL) for 4 days (C and D). Scale bar = 1 µm.

References

    1. Ventola C.L. The antibiotic resistance crisis: Part 2: Management strategies and new agents. P & T. 2015;40:344–352. - PMC - PubMed
    1. Ventola C.L. The antibiotic resistance crisis: Part 1: Causes and threats. P & T. 2015;40:277–283. - PMC - PubMed
    1. De Clercq E., Li G. Approved Antiviral Drugs over the Past 50 Years. Clin. Microbiol. Rev. 2016;29:695–747. doi: 10.1128/CMR.00102-15. - DOI - PMC - PubMed
    1. Rai D., Johar M., Manning T., Agrawal B., Kunimoto D.Y., Kumar R. Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. J. Med. Chem. 2005;48:7012–7017. doi: 10.1021/jm058167w. - DOI - PubMed
    1. Shmalenyuk E.R., Chernousova L.N., Karpenko I.L., Kochetkov S.N., Smirnova T.G., Andreevskaya S.N., Chizhov A.O., Efremenkova O.V., Alexandrova L.A. Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides. Bioorg. Med. Chem. 2013;21:4874–4884. doi: 10.1016/j.bmc.2013.07.003. - DOI - PubMed

MeSH terms